Darunavir and Dasatinib: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Strong CYP3A inhibition increases the named antineoplastic exposure.
Clinical significance and safety
For ritonavir-boosted darunavir (PREZISTA/ritonavir), dasatinib or nilotinib may need specialist modification because exposure can increase. Oncology and HIV teams must review the relevant labels together; do not change either medicine independently.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.